 2. Presence of significant liver disease, malignancy excluding myeloma in the study group, malabsorption syndrome, hypoparathyroidism, hyperparathyroidism, sarcoidosis or hyperthyroidism from toxic multinodular goitre or Graves disease, Pagets disease osteosarcoma, acromegaly, Cushings syndrome, hypopituitarism, diabetes mellitus or severe chronic obstructive pulmonary disease. 